Terumo Cardiovascular names Robert DeRyke as CEO, president
Terumo Cardiovascular Group in Ann Arbor, Michigan, promoted Robert DeRyke to become the company’s CEO and president.
DeRyke was previously president of Terumo Cardiovascular Group’s electromechanical systems division. He replaces Mark Sutter, who retired after serving as CEO and president since 2001.
Before joining Terumo in 2012, DeRyke held executive roles at Baxter Healthcare, Hospira and Thermo-Fisher Scientific.
In 2011, Terumo Cardiovascular Group agreed to a consent decree with the FDA regarding violations at its plant in Ann Arbor, Michigan. As part of the deal, Terumo was prohibited from manufacturing and distributing two of its heart-lung bypass systems and other cardiovascular devices to new customers. The company also agreed to pay $35 million. The FDA lifted all shipping restrictions from the Ann Arbor facility in June 2016.
Terumo plans on returning its advanced perfusion system I heart-lung machine in June. The plans also expects to introduce a new CAPIOX oxygenator and CDI inline blood gas monitoring system later this year, according to a news release.